

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5243227

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BERNARD CHRISTOPHE BARLAAM	05/27/2015
KURT GORDON PIKE	05/20/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ASTRAZENECA UK LIMITED
<b>Street Address:</b>	1 FRANCIS CRICK AVENUE
<b>Internal Address:</b>	CAMBRIDGE BIOMEDICAL CAMPUS
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	CB2 0AA
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15785974
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(301)398-9306
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3013980000
<b>Email:</b>	patents@astrazeneca.com
<b>Correspondent Name:</b>	ASTRAZENECA MEDIMMUNE
<b>Address Line 1:</b>	ONE MEDIMMUNE WAY
<b>Address Line 4:</b>	GAITHERSBURG, MARYLAND 20878
<b>ATTORNEY DOCKET NUMBER:</b>	200222-US-CNT[2]
<b>NAME OF SUBMITTER:</b>	KIM NOROOZI
<b>SIGNATURE:</b>	/Kim Noroozi/
<b>DATE SIGNED:</b>	11/19/2018
<b>Total Attachments: 3</b>	
source=2015_05_27_executed_Barlaam_etal#page1.tif	
source=2015_05_27_executed_Barlaam_etal#page2.tif	
source=2015_05_27_executed_Barlaam_etal#page3.tif	

THIS CONFIRMATORY ASSIGNMENT is made the 5th day of May 2015 (the "Effective Date")

BY AND BETWEEN

Bernard Christophe BARLAAM a French citizen of AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom and Kurt Gordon PIKE a British citizen of AstraZeneca R&D Cambridge, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0FZ, United Kingdom (the "Inventor(s)")

AND

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under No. 3674842 with registered office address at 2 Kingdom Street, London, England W2 6BD ("AstraZeneca")

Recitals

WHEREAS

- A. The Inventor(s) has/have made certain inventions (the "Inventions") in respect of which the patent application(s) specified in the attached Schedule have been filed (the "Patent Application(s)").
- B. The Inventor(s) was/were at all relevant times an employee of AstraZeneca.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of the amounts paid to the Inventor(s) pursuant to their contract of employment with AstraZeneca, the Inventor(s) hereby confirms that by virtue of his/her employment with AstraZeneca, he/she has assigned and does hereby assign, with full title guarantee, free from all and any charges or other third party rights, to AstraZeneca absolutely all his/her right, title and interest in and to the Inventions, the Patent Application(s) and any Patents; any divisions, continuations and continuations-in-part of the Patent Application(s); any re-issues, re-examinations, or extensions of any and all Patents; the right to file patent applications directly in the name of AstraZeneca or an affiliated company of AstraZeneca (in countries or regions where filings are permissible); and the right to claim priority rights deriving from the Patent Application(s) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended and in so far as there may be any outstanding Rights that have not been assigned to AstraZeneca. Inventor (s) warrants that the Rights are unencumbered. The Inventor(s) acknowledge that AstraZeneca shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and the Inventor waives any right of first refusal that they may have for acquiring such Rights. The Inventor(s) further acknowledge that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of One GBP (£1.00).
2. The Inventor(s) each hereby agrees with AstraZeneca that their assignment to AstraZeneca includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Patent Applications, including all rights to recover damages, profits and injunctive relief for infringement of any of the Patent Application(s).
3. The Inventor(s) hereby agrees with AstraZeneca that they will execute such further documents and give such assistance at the expense of AstraZeneca as AstraZeneca may require:
  - a) to secure the vesting in AstraZeneca of all rights in the Patent Application(s) and in such parties to whom AstraZeneca may assign its rights in the Patent Application(s);
  - b) to defeat any challenge to the validity of and resolve any questions concerning the Patent Application(s); and
  - c) to apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Patent Application(s), including the right to claim convention priority from such application(s) and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. The Inventor(s), on behalf of itself and its successors, assigns, nominees, or other legal representatives, does hereby covenant and agree with AstraZeneca that they shall, at the expense of AstraZeneca, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by AstraZeneca to enable AstraZeneca or its successors, nominees or assigns to enjoy the full benefit of the rights assigned by this agreement.

5. The Inventor(s), on behalf of itself and its successors, assigns, nominees, or other legal representatives, does hereby authorize AstraZeneca, its successors, assigns, or nominees, including its patent agents, to amend the present assignment document to insert or correct the filing date, serial number of other identifying information of the Patent Application(s) and/or Patents as may be needed to record same.

6. AstraZeneca accepts the above assignment.

7. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

This agreement has been entered into on the date stated at the beginning of it.


Signed at: Cheshire, UK

Signed at: Cambridge, UK

Date: 27.05. 2015


Date: 20<sup>TH</sup> MAY 2015


  
Bernard Christophe BARLAAM

  
Kurt Gordon PIKE

Witnessed by:


Witnessed by:

  
Name: JENNIFER PENNINGTON


  
Name: Sara Stewart Scott

Signed at: Cheshire, UK

Date: 20<sup>TH</sup> MAY 2015

  
Signed for and on behalf of  
ASTRAZENECA UK LIMITED  
Name: Lucy PADGET  
Capacity: Authorised Signatory

Witnessed by:

  
Name: Jennifer Pennington

**THE SCHEDULE**

<b>THE PATENT APPLICATION(S)</b>					
<b>AstraZeneca Case No:</b>	<b>Application Ref:</b>	<b>Country</b>	<b>Filing Type</b>	<b>Application No. and/or Title of Invention</b>	<b>Filing Date</b>
200222-AR-NP	A	Argentina	National	20150101395	7th May 2015
200222-BO-NP	B	Bolivia	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-WO-PCT	C	International	PCT	PCT/GB2015/051312	5th May 2015
200222-LB-NP	D	Lebanon	National	10640	8th May 2015
200222-PY-NP	E	Paraguay	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-PK-NP	F	Pakistan	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-TW-NP	G	Taiwan	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-UY-NP	H	Uruguay	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-US-NP	I	USA	National	14/704031	5th May 2015
200222-VE-NP	J	Venezuela	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-BS-NP	K*	Bahamas	National	Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer	To be advised
200222-JM-NP	L*	Jamaica	National	18/1/5670	23rd Apr 2015

Patent Application(s) referenced A to J inclusive claim priority from the following US Provisional Application(s)

<b>Application No.</b>	<b>Filing Date</b>
61/990232	8th May 2014

Patent Application(s) referenced K\* and L\* do not claim priority

**PATENT**